Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Caris Life Sciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Revenue
306
412
812
Research and development
117
114
102
Selling and marketing
143
153
168
General and administrative
149
169
225
Operating income
-320
-257
45.1
Interest expense
31.6
50
56.9
Interest income
11.3
7.12
16.5
Other non-operating income
-21.9
-24.8
-113
Pre-tax income
-341
-282
-68.1
Income tax
0
0
0
Net income
-341
-282
-68.1
EBITDA
-271
-208
67.7
EPS, basic
-13.24
-10.66
-3.22
EPS, diluted
-13.24
-10.66
-3.22
Shares, basic (weighted)
34.9
35.5
167
Shares, diluted (weighted)
34.9
35.5
167
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
64
796
Short-term investments
2.2
2.3
Receivables
88.2
112
Other current assets
6.71
2.36
Total current assets
216
998
Property, plant and equipment
67.8
63.2
Lease right-of-use assets
35
39.8
Goodwill
19.3
19.3
Other non-current assets
40.8
45.3
Total assets
344
1,126
Accounts payable
27.8
39.2
Accrued liabilities
77.5
87.8
Deferred revenue
7.47
24.5
Short-term debt
60.1
0.17
Total current liabilities
165
127
Long-term debt
319
379
Lease liabilities
38.7
42.3
Other non-current liabilities
44.4
42.4
Total liabilities
621
548
Total debt
373
378
Paid-in capital
0
3,142
Retained earnings
-2,472
-2,549
Treasury stock
-0.33
-16.9
Other comprehensive income
0.21
0.94
Shareholders' equity
-2,145
-2,499
577
Total equity
-2,145
-2,499
577
Total liabilities and equity
344
1,126
Shares outstanding
36.5
283
Cash flow statement
FY2023
FY2025
FY2025
Net income
-341
-282
-68.1
Depreciation and amortization
49
48.9
22.6
Stock-based compensation
15.2
18.6
70
Change in receivables
-15.1
-33.8
-29.8
Change in payables
7.17
-0.23
11
Cash from operations
-276
-245
83.2
Capital expenditures
-22.3
-8.44
-16.3
Purchases of investments
-63.4
0
0
Sales and maturities of investments
300
61.4
0
Cash from investing
215
52.9
-16.3
Stock issued
1.87
1.53
7.64
Share buybacks
0
0
-0.11
Cash from financing
10.1
200
665
Net change in cash
-51.1
8.02
732
Free cash flow
-298
-254
66.9
Interest paid
15.8
49
43.5
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $31.98 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
15.5%
Operating income / revenue.
EBITDA margin
17.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
10.6%
Pre-tax income / revenue.
Net margin
10.6%
Net income / revenue.
Operating cash flow margin
17.0%
Cash from operations / revenue.
Effective tax rate
-0.1%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
17.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
8.6%
Net income / average total assets.
Return on invested capital (ROIC)
12.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
11.8%
Research and development expense / revenue.
Stock-based pay / revenue
6.6%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
2.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
97.0%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
227.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
371.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.53x
Current assets / current liabilities.
Debt / equity
0.66x
Total debt / shareholders' equity. Not shown when equity is negative.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.50
Revenue / diluted weighted shares.
Operating cash flow per share
$0.60
Cash from operations / diluted weighted shares.
Book value per share
$2.09
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share
$2.03
Tangible book value / shares outstanding.
Valuation
Metric
Value
How it is calculated
Market cap
$9.04B
Share price x shares outstanding.
Enterprise value
$9.33B
Market cap + total debt - cash - short-term investments.
P/E
86.0x
Market cap / net income. Only when net income is positive.
P/S
9.13x
Market cap / revenue.
P/B
15.3x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
15.8x
Market cap / tangible book value, when positive.
P/OCF
53.6x
Market cap / cash from operations, when positive.
EV/Sales
9.43x
Enterprise value / revenue.
EV/EBIT
60.9x
Enterprise value / operating income, when both are positive.
EV/EBITDA
53.6x
Enterprise value / EBITDA, when both are positive.
Earnings yield
1.2%
Net income / market cap (the inverse of P/E).
Shareholder yield
0.2%
(Dividends paid + share buybacks) / market cap.
What was Caris Life Sciences, Inc.'s revenue in fiscal 2025?
Caris Life Sciences, Inc. reported revenue of $812.0M for fiscal 2025, 97% higher than the year before.
Was Caris Life Sciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $68.1M.
How much free cash flow did Caris Life Sciences, Inc. generate in fiscal 2025?
Cash from operations of $83.2M minus capital expenditures of $16.3M left free cash flow of $66.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.